title: Acanthopanax senticosus reverses fatty liver disease and hyperglycemia in ob/ob mice.
abstract: Non-alcoholic fatty liver disease (NAFLD) is common in obesity. However, weight reduction alone does not prevent the progression of NAFLD to end-stage disease associated with the development of cirrhosis and liver disease. In a previous experiment, 50% ethanol extract of Acanthopanax senticosus stem bark (ASSB) was found to reduce body weight and insulin resistance in high fat diet-induced hyperglycemic and hyperlipidemic ICR mice. To evaluate the anti-steatosis action of ASSB, insulin-resistant ob/ob mice with fatty livers were treated with ASSB ethanol extract for an 8 week-period. ASSB ethanol extract reversed the hepatomegaly, as evident in reduction of % liver weight/body weight ratio. ASSB ethanol extract also specifically lowered circulating glucose and lipids, and enhanced insulin action in the liver. These changes culminated in inhibition of triglyceride synthesis in non-adipose tissues including liver and skeletal muscle. Gene expression studies confirmed reductions in glucose 6-phosphatase and lipogenic enzymes in the liver. These results demonstrate that ASSB ethanol extract is an effective treatment for insulin resistance and hepatic steatosis in ob/ob mice by decreasing hepatic lipid synthesis.
authors.affiliation: College of Pharmacy, Kyung Hee University, Seoul 130-701, Korea.
authors.forename: Sang Hyun
authors.initials: SH
authors.lastname: Park
authors.forename: Sang Gil
authors.initials: SG
authors.lastname: Lee
authors.forename: Sung Keel
authors.initials: SK
authors.lastname: Kang
authors.forename: Sung Hyun
authors.initials: SH
authors.lastname: Chung
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D028001:Eleutherococcus / Q000737:chemistry*; D000431:Ethanol; D005234:Fatty Liver / Q000188:drug therapy* / Q000473:pathology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D005951:Glucose Tolerance Test; D005954:Glucosephosphate Dehydrogenase / Q000378:metabolism; D006943:Hyperglycemia / Q000188:drug therapy*; D006949:Hyperlipidemias / Q000188:drug therapy; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000096:biosynthesis; D008099:Liver / Q000473:pathology; D051379:Mice; D008813:Mice, Inbred ICR; D008820:Mice, Obese; D019764:Phosphoenolpyruvate Carboxykinase (ATP) / Q000378:metabolism; D010936:Plant Extracts / Q000627:therapeutic use; D012313:RNA / Q000096:biosynthesis / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012997:Solvents; D014280:Triglycerides / Q000097:blood; D015430:Weight Gain / Q000187:drug effects
chemical_list: D007328:Insulin; D008055:Lipids; D010936:Plant Extracts; D012997:Solvents; D014280:Triglycerides; D000431:Ethanol; D012313:RNA; D005954:Glucosephosphate Dehydrogenase; D019764:Phosphoenolpyruvate Carboxykinase (ATP)